Equus Total Return, Inc. (EQS) · Oct 13, 2026 · Other events
$1 listing deficiency — 30-day average closing price below $1.00; six-month cure period
Equus Total Return received an NYSE listing-deficiency notice after its average share price stayed below $1. The stock remains listed, but a cure is required.
Equus is trying to transition from a business development company into an operating company, but its immediate problem is maintaining the NYSE platform needed for that strategy. The company says it is evaluating an acquisition or merger with an operating business to end its BDC status, making continued exchange access more than a technical detail.
The filing confirms a genuine listing deficiency, not an imminent delisting. Equus was notified that its average closing price fell below the NYSE’s $1.00 minimum for 30 consecutive trading days. The shares remain listed and trading for now, with a six-month window to restore both the month-end closing price and the trailing 30-day average to at least $1.00.
The practical response may involve shareholder-approved capital-structure action. Equus says it will consider several remedies, explicitly including a reverse stock split. 〔0〕 That does not change the operating business today, but it adds execution risk and could complicate the company’s broader effort to reposition itself.
Bottom line: This is not a delisting, but it is a new warning that Equus’s weak share price has become a business constraint. The immediate story is a compliance timetable, with a reverse split now a live possibility rather than a remote theoretical remedy.,
Cure plan due to NYSE by October 20, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!